Investigator-assessed best overall response
| Investigator-assessed response . | Primary cohort (N = 24) . | ITT population (N = 55) . | BRAF V600E evaluable population (n = 50) . |
|---|---|---|---|
| Best response, n (%) | |||
| CR ± MRD | 18 (75.0) | 36 (65.5) | 32 (64.0) |
| CR without MRD | 4 (16.7)∗ | 5 (9.1)∗ | 4 (8.0)∗ |
| 5 (20.8)† | 7 (12.7)† | 6 (12.0)† | |
| CR with MRD | 5 (20.8)‡ | 9 (16.4)‡ | 7 (14.0)‡ |
| 13 (54.2) | 27 (49.1) | 25 (50.0) | |
| PR | 4 (16.7) | 13 (23.6) | 13 (26.0) |
| Minor response | 1 (4.2) | 4 (7.3) | 4 (8.0) |
| Stable disease | 0 | 0 | 0 |
| Progressive disease | 1 (4.2) | 1 (1.8) | 1 (2.0) |
| Not evaluable | 0 | 1 (1.8) | 0 |
| ORR (CR ± MRD + PR), n (%) | 22 (91.7) | 49 (89.1) | 45 (90.0) |
| 95% CI§ | 73.0-99.0 | 77.8-95.9 | 78.2-96.7 |
| Investigator-assessed response . | Primary cohort (N = 24) . | ITT population (N = 55) . | BRAF V600E evaluable population (n = 50) . |
|---|---|---|---|
| Best response, n (%) | |||
| CR ± MRD | 18 (75.0) | 36 (65.5) | 32 (64.0) |
| CR without MRD | 4 (16.7)∗ | 5 (9.1)∗ | 4 (8.0)∗ |
| 5 (20.8)† | 7 (12.7)† | 6 (12.0)† | |
| CR with MRD | 5 (20.8)‡ | 9 (16.4)‡ | 7 (14.0)‡ |
| 13 (54.2) | 27 (49.1) | 25 (50.0) | |
| PR | 4 (16.7) | 13 (23.6) | 13 (26.0) |
| Minor response | 1 (4.2) | 4 (7.3) | 4 (8.0) |
| Stable disease | 0 | 0 | 0 |
| Progressive disease | 1 (4.2) | 1 (1.8) | 1 (2.0) |
| Not evaluable | 0 | 1 (1.8) | 0 |
| ORR (CR ± MRD + PR), n (%) | 22 (91.7) | 49 (89.1) | 45 (90.0) |
| 95% CI§ | 73.0-99.0 | 77.8-95.9 | 78.2-96.7 |